公开(公告)号：US20190276428A1

公开(公告)日：2019-09-12

申请号：US16335095

申请日：2017-09-21

申请人： KAKEN PHARMACEUTICAL CO., LTD.

发明人： Yoshitake SUMIKAWA ,  Noriyuki KAMEI ,  Shingo TODO

IPC分类号： C07D401/06

摘要： A method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, the method comprising, (a) a step for isolating an isomer represented by formula (2) from a mixture of isomers represented by formula (1), and (b) a step for obtaining (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione by removing the menthyloxycarbonyl group from the compound represented by formula (2), which was isolated in step (a).

公开(公告)号：US20160340349A1

公开(公告)日：2016-11-24

申请号：US15232000

申请日：2016-08-09

申请人： KAKEN PHARMACEUTICAL CO., LTD.

发明人： Noriyuki KAMEI ,  Yoshitake SUMIKAWA ,  Daigo KAMIMURA ,  Shingo TODO ,  Takuya YAMADA ,  Shota TOKUOKA

IPC分类号： C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07D401/06 ,  C07D409/14

CPC分类号： C07D413/14 ,  C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

摘要： General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ring A, R1, R2, R3 and R4 are specific groups.]

公开(公告)号：US20160130248A1

公开(公告)日：2016-05-12

申请号：US14895768

申请日：2014-06-06

申请人： KAKEN PHARMACEUTICAL CO., LTD.

发明人： Noriyuki KAMEI ,  Daigo KAMIMURA ,  Yoshitake SUMIKAWA ,  Shota TOKUOKA

IPC分类号： C07D401/06

CPC分类号： C07D401/06 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/4439 ,  A61K47/10 ,  A61K2300/00

摘要： Provided is (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof. Also provided is a drug containing as the active ingredient (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

摘要翻译： 提供（+） - 5-（3,4-二氟苯基）-5 - [（3-甲基-2-氧代吡啶-1（2H） - 基）甲基]咪唑烷-2,4-二酮或其盐。 还提供含有作为活性成分（+） - 5-（3,4-二氟苯基）-5 - [（3-甲基-2-氧代吡啶-1（2H） - 基）甲基]咪唑烷-2,4 - 二酮或其盐。

公开(公告)号：US20230086366A1

公开(公告)日：2023-03-23

申请号：US17268649

申请日：2019-09-09

申请人： KAKEN PHARMACEUTICAL CO., LTD.

发明人： Issei AKAHOSHI ,  Yoshitake SUMIKAWA ,  Sadayoshi FURUTA ,  Keiichiro FUKUSHIMA ,  Takuya IMAZU ,  Ryota KOTAKA

IPC分类号： C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  A61P25/04

摘要： A heteroaromatic amide derivative or salt thereof showing high efficacy for diseases associated with Nav1.7 is represented by general formula (I) [wherein, X1-X2 is N—C or C—N, Y1, Y2, Y3 and Y4 are —CH2—, —CR4aH— or —O— and so on, Z1 is —O— and so on, ring A is a 3- to 7-membered monocyclic aromatic ring and so on, R1a and R1b are a hydrogen atom or a halogen atom and so on, R2 is a hydrogen atom and so on, R3a, R3b and R3c are a hydrogen atom or an optionally substituted C1-C6 haloalkyl group and so on, R4a, R4b and R4c are, an optionally substituted C1-C6 haloalkyl group or C1-C6 haloalkoxy group and so on, R5a is a hydrogen atom and so on, R5a and R5b together form —CH2O— and so on, R6a and R6b are a hydrogen atom and so on, n is 1 or 2.].